Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 105

1.

Use of bisphosphonates among women and risk of atrial fibrillation and flutter: population based case-control study.

Sørensen HT, Christensen S, Mehnert F, Pedersen L, Chapurlat RD, Cummings SR, Baron JA.

BMJ. 2008 Apr 12;336(7648):813-6. doi: 10.1136/bmj.39507.551644.BE. Epub 2008 Mar 11.

2.

Risk of atrial fibrillation associated with use of bisphosphonates and other drugs against osteoporosis: a cohort study.

Vestergaard P, Schwartz K, Pinholt EM, Rejnmark L, Mosekilde L.

Calcif Tissue Int. 2010 May;86(5):335-42. doi: 10.1007/s00223-010-9349-0. Epub 2010 Mar 23.

PMID:
20309678
3.

Oral bisphosphonates and risk of ischemic stroke: a case-control study.

Christensen S, Mehnert F, Chapurlat RD, Baron JA, Sørensen HT.

Osteoporos Int. 2011 Jun;22(6):1773-9. doi: 10.1007/s00198-010-1395-y. Epub 2010 Oct 13.

PMID:
20945149
4.

Non-steroidal anti-inflammatory drug use and risk of atrial fibrillation or flutter: population based case-control study.

Schmidt M, Christiansen CF, Mehnert F, Rothman KJ, Sørensen HT.

BMJ. 2011 Jul 4;343:d3450. doi: 10.1136/bmj.d3450.

PMID:
21727167
5.

Intravenous bisphosphonate therapy and atrial fibrillation/flutter risk in cancer patients: a nationwide cohort study.

Erichsen R, Christiansen CF, Frøslev T, Jacobsen J, Sørensen HT.

Br J Cancer. 2011 Sep 27;105(7):881-3. doi: 10.1038/bjc.2011.338. Epub 2011 Aug 30.

6.

Oral bisphosphonates and atrial fibrillation.

Majumdar SR.

BMJ. 2008 Apr 12;336(7648):784-5. doi: 10.1136/bmj.39513.481065.80. Epub 2008 Mar 11. No abstract available.

7.

Risk of atrial fibrillation among bisphosphonate users: a multicenter, population-based, Italian study.

Herrera L, Leal I, Lapi F, Schuemie M, Arcoraci V, Cipriani F, Sessa E, Vaccheri A, Piccinni C, Staniscia T, Vestri A, Di Bari M, Corrao G, Zambon A, Gregori D, Carle F, Sturkenboom M, Mazzaglia G, Trifiro G.

Osteoporos Int. 2015 May;26(5):1499-506. doi: 10.1007/s00198-014-3020-y. Epub 2015 Mar 10.

8.

Oral bisphosphonates and risk of atrial fibrillation and flutter in women: a self-controlled case-series safety analysis.

Grosso A, Douglas I, Hingorani A, MacAllister R, Smeeth L.

PLoS One. 2009;4(3):e4720. doi: 10.1371/journal.pone.0004720. Epub 2009 Mar 6.

9.

Bisphosphonates and atrial fibrillation: systematic review and meta-analysis.

Loke YK, Jeevanantham V, Singh S.

Drug Saf. 2009;32(3):219-28. doi: 10.2165/00002018-200932030-00004. Review.

PMID:
19338379
10.

Osteoporosis treatment and atrial fibrillation: alendronate versus raloxifene.

Huang WF, Tsai YW, Wen YW, Hsiao FY, Kuo KN, Tsai CR.

Menopause. 2010 Jan-Feb;17(1):57-63. doi: 10.1097/gme.0b013e3181b34749.

PMID:
19680161
11.

Glucocorticoid use and risk of atrial fibrillation or flutter: a population-based, case-control study.

Christiansen CF, Christensen S, Mehnert F, Cummings SR, Chapurlat RD, Sørensen HT.

Arch Intern Med. 2009 Oct 12;169(18):1677-83. doi: 10.1001/archinternmed.2009.297.

PMID:
19822824
12.

Risk of atrial fibrillation with use of oral and intravenous bisphosphonates.

Sharma A, Einstein AJ, Vallakati A, Arbab-Zadeh A, Walker MD, Mukherjee D, Homel P, Borer JS, Lichstein E.

Am J Cardiol. 2014 Jun 1;113(11):1815-21. doi: 10.1016/j.amjcard.2014.03.008. Epub 2014 Mar 15. Review.

PMID:
24837258
13.

Oral bisphosphonates and risk of cancer of oesophagus, stomach, and colorectum: case-control analysis within a UK primary care cohort.

Green J, Czanner G, Reeves G, Watson J, Wise L, Beral V.

BMJ. 2010 Sep 1;341:c4444. doi: 10.1136/bmj.c4444.

14.

Statin Use and Risk of Atrial Fibrillation or Flutter: A Population-based Case-Control Study.

Veronese G, Montomoli J, Schmidt M, Horváth-Puhó E, Sørensen HT.

Am J Ther. 2015 May-Jun;22(3):186-94. doi: 10.1097/MJT.0b013e31827ab488.

PMID:
23567792
15.

Use of oral bisphosphonates and risk of venous thromboembolism: a population-based case-control study.

Lamberg AL, Horvath-Puho E, Christensen S, Sørensen HT.

Osteoporos Int. 2010 Nov;21(11):1911-7. doi: 10.1007/s00198-009-1143-3. Epub 2009 Dec 9.

PMID:
19997902
16.

Atrial fibrillation in fracture patients treated with oral bisphosphonates.

Abrahamsen B, Eiken P, Brixen K.

J Intern Med. 2009 May;265(5):581-92. doi: 10.1111/j.1365-2796.2008.02065.x. Epub 2009 Jan 6.

17.

Use of bisphosphonate and risk of atrial fibrillation in older women with osteoporosis.

Rhee CW, Lee J, Oh S, Choi NK, Park BJ.

Osteoporos Int. 2012 Jan;23(1):247-54. doi: 10.1007/s00198-011-1608-z. Epub 2011 Mar 24. Erratum in: Osteoporos Int. 2012 Jan;23(1):255.

PMID:
21431993
18.

[Bisphosphonates and the risk of atrial fibrillation].

Sewerynek E, Stuss M.

Endokrynol Pol. 2011;62 Suppl 3:10-3. Review. Polish.

PMID:
22161981
19.

Bisphosphonates and atrial fibrillation: clinical trial data suggest possible link.

[No authors listed]

Prescrire Int. 2011 Apr;20(115):96-7.

PMID:
21648212
20.

Atrial fibrillation following intravenous zolendronic acid for osteoporosis.

Konsta M, Bournia VK, Dania V, Iliopoulos A.

J Clin Rheumatol. 2014 Jun;20(4):239-40. doi: 10.1097/RHU.0000000000000114. No abstract available.

PMID:
24847757

Supplemental Content

Support Center